Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
801-820 of 1,694 trials

Urinary Incontinence in Children: StayDry Study

We are exploring how stopping medication for urinary incontinence affects recurrence and overall well-being in children. The study compares abrupt versus gradual withdrawal of treatments like solifenacin and mirabegron.

Daytime Urinary Incontinence>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesUrology

Sickle Cell Disease: BMS-986470 Study

We are testing a new medication, BMS-986470, to see if it is safe and well-tolerated in healthy volunteers and people with sickle cell disease. The study aims to find the best dose and evaluate its effects on hemoglobin levels.

Sickle Cell DiseaseSafety phase (I)Efficacy phase (II)Investigational MedicinesHematologyInternal Medicine

Chronic Graft-Versus-Host Disease: Axatilimab Treatment

We are studying whether axatilimab, combined with corticosteroids, helps improve symptoms in patients with moderate to severe chronic graft-versus-host disease. This trial compares its effects to a placebo.

Chronic Graft-Versus-Host DiseaseConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Chronic Lymphocytic Leukemia: Venetoclax and Pirtobrutinib Study

We are comparing different treatment plans for newly diagnosed chronic lymphocytic leukemia patients to see if a personalized approach improves outcomes. This includes assessing how long patients can stay in remission and the overall effectiveness of the treatments.

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Hypereosinophilic Syndrome: Depemokimab Study

We are investigating whether Depemokimab can help adults with Hypereosinophilic Syndrome manage their symptoms better than a placebo. This study aims to provide insights into its effectiveness and safety.

Hypereosinophilic Syndrome1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Carvedilol vs. Flecainide for Ventricular Arrhythmias

We are comparing two medications to see which one better reduces abnormal heartbeats in people with idiopathic ventricular arrhythmias. The study also looks at how these treatments affect quality of life and any side effects.

Ventricular ExtrasystolesMonomorphic Ventricular TachycardiaIdiopathic Ventricular Arrhythmias6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiology

Metformin for Prolonging Pregnancy in Preterm Preeclampsia

We are studying whether metformin can help extend pregnancy by at least 5 days in individuals with preterm preeclampsia. Additionally, we aim to see if it improves health outcomes for mothers and their babies.

Pre-eclampsiaHELLP SyndromeHypertensive Disorders of Pregnancy>2 yearsConfirmation phase (III)Investigational MedicinesGynecology and ObstetricsInternal Medicine

Multiple Myeloma: Teclistamab with Lenalidomide

We are studying a new treatment combining teclistamab and lenalidomide for patients with newly diagnosed multiple myeloma after stem cell transplant. The aim is to see if this combination works better than lenalidomide alone in maintaining remission.

Newly Diagnosed Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Benzodiazepine Dependence: Stabilizing Treatment Study

We are examining how a stable dose of benzodiazepines affects people with benzodiazepine dependence who are also receiving opioid therapy. The study looks at impacts on drug use, mental and physical health, and overall quality of life.

Benzodiazepine Dependence1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePsychiatry

Crigler-Najjar Syndrome: GNT0003 Treatment Study

We are evaluating a new treatment called GNT0003 for adults with severe Crigler-Najjar syndrome who need daily phototherapy. The study aims to see if this treatment is safe and effective for those with pre-existing antibodies.

Crigler-Najjar Syndrome>2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInternal Medicine

Brivaracetam for Childhood Absence Epilepsy

We are studying whether brivaracetam is effective and safe for children and young adults aged 2 to 25 with childhood or juvenile absence epilepsy. This trial aims to provide insights into its use as a standalone treatment.

Childhood Absence Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

HER2-Altered Cancers: Zongertinib Study

We are testing whether zongertinib can help people with advanced solid tumors that have HER2 mutations or overexpression. The study will evaluate its effectiveness, safety, and how patients respond to the treatment.

HER2-mutated or overexpressed/amplified solid tumorsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Meningococcal Disease: New Pentavalent Vaccine for Children

We are studying a new vaccine to see if it is safe and effective for healthy children, toddlers, and infants against meningococcal disease. The trial compares this vaccine with currently licensed options to evaluate immune responses.

Meningococcal Immunization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Psilocybin Therapy for Depression in Serious Illnesses

We are studying whether medium/high doses of psilocybin can help reduce depression and anxiety in patients with COPD, ALS, MS, or APD. This research aims to improve their quality of life and support their caregivers.

Chronic Respiratory and Neurological Disorders≤3 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryPulmonology

Pancreatic Cancer: Organoid-Based Treatment Selection

We are studying whether lab-grown mini-tumors can help choose better post-surgery treatments for patients with resectable pancreatic cancer. This may improve recovery and outcomes after surgery.

Pancreatic Ductal Adenocarcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Interstitial Lung Disease: Rituximab and Mycophenolate Combination

We are studying a combination of rituximab and mycophenolate mofetil for patients with interstitial lung disease related to systemic sclerosis. The goal is to see if this treatment improves lung function and overall health compared to a placebo.

Lung Involvement in Systemic Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesPulmonologyRheumatology

Acute Myeloid Leukemia: KO-539 Treatment Study

We are testing a new drug called KO-539 in patients with relapsed or refractory acute myeloid leukemia. The goal is to see if it is safe and effective for those with specific genetic mutations.

Relapsed Acute Myeloid Leukemia≤3 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

B-Cell Acute Lymphoblastic Leukemia: Inotuzumab Ozogamicin Study

We are examining whether Inotuzumab can help adults with B-Cell Acute Lymphoblastic Leukemia achieve MRD negativity before stem cell transplantation. The study will also look at treatment safety and survival rates.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Obstructive Sleep Apnea: Sulthiam and Oral Appliance Study

We are studying whether adding the medication sulthiam to an oral appliance helps patients with obstructive sleep apnea who aren't getting enough relief from their current treatment. This trial will also look for specific biomarkers related to their condition.

Obstructive Sleep ApneaEfficacy phase (II)Investigational MedicinesInternal MedicinePulmonology

ANCA-Associated Vasculitis: LNP023 (iptacopan) Study

We are testing a new treatment for patients with active ANCA-associated vasculitis to see if it helps achieve lasting remission compared to standard care. The study will also evaluate its impact on disease relapse and kidney health.

Microscopic PolyangiitisGranulomatosis with Polyangiitis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology